Top

Published in:

Open Access 01-11-2010 | REVIEW

Osteoporosis Therapies: Evidence from Health-Care Databases and Observational Population Studies

Author: Stuart L. Silverman

Published in: Calcified Tissue International | Issue 5/2010

Abstract

Osteoporosis is a well-recognized disease with severe consequences if left untreated. Randomized controlled trials are the most rigorous method for determining the efficacy and safety of therapies. Nevertheless, randomized controlled trials underrepresent the real-world patient population and are costly in both time and money. Modern technology has enabled researchers to use information gathered from large health-care or medical-claims databases to assess the practical utilization of available therapies in appropriate patients. Observational database studies lack randomization but, if carefully designed and successfully completed, can provide valuable information that complements results obtained from randomized controlled trials and extends our knowledge to real-world clinical patients. Randomized controlled trials comparing fracture outcomes among osteoporosis therapies are difficult to perform. In this regard, large observational database studies could be useful in identifying clinically important differences among therapeutic options. Database studies can also provide important information with regard to osteoporosis prevalence, health economics, and compliance and persistence with treatment. This article describes the strengths and limitations of both randomized controlled trials and observational database studies, discusses considerations for observational study design, and reviews a wealth of information generated by database studies in the field of osteoporosis.

Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A (2007) Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res 22:465–475CrossRefPubMed

Lindsay R, Borisov NN, Sheer RL, Steinbuch M (2005) Impact of early osteoporosis treatment on subsequent fracture prevention among women with clinical vertebral fracture. Presented at: Annual Meeting of the American Society for Bone and Mineral Research, September 23–27, Nashville, TN, abstract M293

Downey TW, Foltz SH, Boccuzzi SJ, Omar MA, Kahler KH (2006) Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting. South Med J 99:570–575CrossRefPubMed

Lo JC, Pressman AR, Omar MA, Ettinger B (2006) Persistence with weekly alendronate therapy among postmenopausal women. Osteoporos Int 17:922–928CrossRefPubMed

Stables RH (2002) Observational research in the evidence based environment: eclipsed by the randomised controlled trials? Heart 87:101–102CrossRefPubMed

Hannan EL (2008) Randomized clinical trials and observational studies: guidelines for assessing respective strengths and limitations. J Am Coll Cardiol Intv 1:211–217

Motheral BR, Fairman KA (1997) The use of claims databases for outcomes research: rationale, challenges, and strategies. Clin Ther 19:346–366CrossRefPubMed

Dowd R, Recker RR, Heaney RP (2000) Study subjects and ordinary patients. Osteoporos Int 11:533–536CrossRefPubMed

Ward LC, Fielding JW, Dunn JA, Kelly KA (1992) The selection of cases for randomised trials: a registry survey of concurrent trial and non-trial patients. The British Stomach Cancer Group. Br J Cancer 66:943–950PubMed

10.

Cziraky MJ, Willey VJ, McKenney JM, Kamat SA, Fisher MD, Guyton JR et al (2006) Statin safety: an assessment using an administrative claims database. Am J Cardiol 97:61C–68CCrossRefPubMed

11.

Vray M, Hamelin B, Jaillon P; Round Table 2, Giens XX (2005) The respective roles of controlled clinical trials and cohort monitoring studies in the pre- and postmarketing assessment of drugs. Therapie 60:339–344

12.

Ayanian JZ (1999) Using administrative data to assess health care outcomes. Eur Heart J 20:1689–1691CrossRefPubMed

13.

Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott JA et al (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81:1013–1022CrossRefPubMed

14.

Cramer JA, Gold DT, Silverman SL, Lewiecki EM (2007) A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 18:1023–1031CrossRefPubMed

15.

Van Staa TP, Geusens P, Leufkens HG, Cooper C (2005) Persistence to bisphosphonate treatment in actual clinical practice. Second joint meeting of the European Calcified Tissue Society and the International Bone and Mineral Society, 25–29 June, Geneva, Switzerland, abstract P610-Su

16.

Couris CM, Duclos A, Rabilloud M, Couray-Targe S, Ecochard R, Delmas PD et al (2007) A seventy percent overestimation of the burden of hip fractures in women aged 85 and over. Bone 41:896–900CrossRefPubMed

17.

Jaglal SB, Weller I, Mamdani M, Hawker G, Kreder H, Jaakkimainen L et al (2005) Population trends in BMD testing, treatment, and hip and wrist fracture rates: are the hip fracture projections wrong? J Bone Miner Res 20:898–905CrossRefPubMed

18.

Chevalley T, Guilley E, Herrmann FR, Hoffmeyer P, Rapin CH, Rizzoli R (2007) Incidence of hip fracture over a 10-year period (1991–2000): reversal of a secular trend. Bone 40:1284–1289CrossRefPubMed

19.

Borgström F, Zethraeus N, Johnell O, Lidgren L, Ponzer S, Svensson O et al (2006) Costs and quality of life associated with osteoporosis-related fractures in Sweden. Osteoporos Int 17:637–650CrossRefPubMed

20.

Black N (1996) Why we need observational studies to evaluate the effectiveness of health care. BMJ 312:1215–1218PubMed

21.

Lobo FS, Wagner S, Gross CR, Schommer JC (2006) Addressing the issue of channeling bias in observational studies with propensity scores analysis. Res Social Adm Pharm 2:143–151PubMed

22.

Hartz A, Bentler S, Charlton M, Lanska D, Butani Y, Soomro GM et al (2005) Assessing observational studies of medical treatments. Emerg Themes Epidemiol 2:8CrossRefPubMed

23.

Benson K, Hartz AJ (2000) A comparison of observational studies and randomized, controlled trials. N Engl J Med 342:1878–1886CrossRefPubMed

24.

Concato J, Shah N, Horwitz RI (2000) Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 342:1887–1892CrossRefPubMed

25.

Wei L, Ebrahim S, Bartlett C, Davey PD, Sullivan FM, McDonald TM (2005) Statin use in the secondary prevention of coronary heart disease in primary care: cohort study and comparison of inclusion and outcome with patients in randomised trials. BMJ 330:821CrossRefPubMed

26.

Gross CP, Krumholz HM, Van Wye G, Emanuel EJ, Wendler D (2006) Does random treatment assignment cause harm to research participants? PLoS Med 3:e188CrossRefPubMed

27.

King AB, Saag KG, Burge RT, Pisu M, Goel N (2005) Fracture Reduction Affects Medicare Economics (FRAME): impact of increased osteoporosis diagnosis and treatment. Osteoporos Int 16:1545–1557CrossRefPubMed

28.

Sørensen HT, Lash TL, Rothman KJ (2006) Beyond randomized controlled trials: a critical comparison of trials with nonrandomized studies. Hepatology 44:1075–1082CrossRefPubMed

29.

International Osteoporosis Foundation (2010) International costs and utilities related to osteoporotic fractures study (ICUROS), http://www.iofbonehealth.org/health-professionals/health-economics/icuros.html. Cited 23 March 2010

30.

Weiss TW, Gold DT, Silverman SL, McHorney CA (2006) An evaluation of patient preferences for osteoporosis medication attributes: results from the PREFER-US study. Curr Med Res Opin 22:949–960CrossRefPubMed

31.

Keen R, Jodar E, Iolascon G, Kruse HP, Varbanov A, Mann B et al (2006) European women’s preference for osteoporosis treatment: influence of clinical effectiveness and dosing frequency. Curr Med Res Opin 22:2375–2381CrossRefPubMed

32.

Gold DT, Safi W, Trinh H (2006) Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate. Curr Med Res Opin 22:2383–2391CrossRefPubMed

33.

Gallagher AM, Rietbrock S, Olson M, van Staa TP (2008) Fracture outcomes related to persistence and compliance with oral bisphosphonates. J Bone Miner Res 23:1569–1575CrossRefPubMed

34.

Rabenda V, Mertens R, Fabri V, Vanoverloop J, Sumkay F, Vannecke C et al (2008) Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int 19:811–818CrossRefPubMed

35.

Gold DT, Martin BC, Frytak JR, Amonkar MM, Cosman F (2007) A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis. Curr Med Res Opin 23:585–594CrossRefPubMed

36.

Silverman S (2006) Adherence to medications for the treatment of osteoporosis. Rheum Dis Clin North Am 32:721–731CrossRefPubMed

37.

Gold DT, McClung B (2006) Approaches to patient education: emphasizing the long-term value of compliance and persistence. Am J Med 119(4 Suppl 1):S32–S37CrossRefPubMed

38.

Cotte FE, Fardellone P, Mercier F, Gaudin AF, Roux C (2010) Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis. Osteoporos Int 21:145–155CrossRefPubMed

39.

Gold DT, Trinh H, Safi W (2009) Weekly versus monthly drug regimens: 1-year compliance and persistence with bisphosphonate therapy. Curr Med Res Opin 25:1831–1839CrossRefPubMed

40.

Bone HG, Hosking D, Devogelaer J-P, Tucci JR, Emkey RD, Tonino RP et al (2004) Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350:1189–1199CrossRefPubMed

41.

Mellström DD, Sörensen OH, Goemaere S, Roux C, Johnson TD, Chines AA (2004) Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 75:462–468CrossRefPubMed

42.

Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809–1822CrossRefPubMed

43.

Heckbert SR, Li G, Cummings SR, Smith NL, Psaty BM (2008) Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med 168:826–831CrossRefPubMed

44.

Sørensen HT, Christensen S, Mehnert F, Pedersen L, Chapurlat RD, Cummings SR et al (2008) Use of bisphosphonates among women and risk of atrial fibrilation and flutter: population base case-control study. BMJ 336:813–816CrossRefPubMed

45.

Bunch TJ, Anderson JL, May HT, Muhlestein JB, Horne BD, Crandall BG et al (2009) Relation of bisphosphonate therapies and risk of developing atrial fibrillation. Am J Cardiol 103:824–828CrossRefPubMed

46.

Abrahamsen B, Eiken P, Eastell R (2009) Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res 24:1095–1102CrossRefPubMed

47.

Wysowski DK (2009) Reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 360:89–90CrossRefPubMed

48.

Watts NB, Worley K, Solis A, Doyle J, Sheer R (2004) Comparison of risedronate to alendronate and calcitonin for early reduction of nonvertebral fracture risk: results from a managed care administrative claims database. J Manag Care Pharm 10:142–151PubMed

49.

Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC et al (2000) Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 85:4118–4124CrossRefPubMed

50.

Harrington JT, Ste-Marie LG, Brandi ML, Civitelli R, Fardellone P, Grauer A et al (2004) Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int 74:129–135CrossRefPubMed

51.

Cadarette SM, Katz JN, Brookhart MA, Sturmer T, Stedman MR, Solomon DH (2008) Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture. Ann Intern Med 148:637–646PubMed

52.

Silverman SL, Watts NB, Delmas PD, Lange JL, Lindsay R (2007) Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. Osteoporos Int 18:25–34CrossRefPubMed

53.

North American Menopause Society (2006) Management of osteoporosis in postmenopausal women: 2006 position statement of The North American Menopause Society. Menopause 13:340–367CrossRef

54.

Rosen CJ, Hochberg MC, Bonnick SL, McClung M, Miller P, Broy S et al (2005) Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res 20:141–151CrossRefPubMed

55.

Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535–1541CrossRefPubMed

56.

Liberman UA, Weiss SR, Bröll J, Minne HW, Quan H, Bell NH et al (1995) Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 333:1437–1443CrossRefPubMed

57.

Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA et al (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280:2077–2082CrossRefPubMed

58.

Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 282:1344–1352CrossRefPubMed

59.

Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML et al (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11:83–91CrossRefPubMed

60.

Curtis JR, Westfall AO, Cheng H, Saag KG, Delzell E (2009) Risedronate and Alendronate Intervention over Three Years (REALITY): minimal differences in fracture risk reduction. Osteoporos Int 20:973–978CrossRefPubMed

61.

Harris ST, Reginster JY, Harley C, Blumentals WA, Poston SA, Barr CE et al (2009) Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: the Evaluation of Ibandronate Efficacy (VIBE) database fracture study. Bone 44:758–765CrossRefPubMed

62.

Abelson A, Ringe JD, Gold DT, Lange JL, Thomas T (2009) Longitudinal change in clinical fracture incidence after initiation of bisphosphonates. Osteoporos Int. doi:10.1007/s00198-009-1046-3

63.

Miller PD, Silverman SL, Gold DT, Taylor KA, Chen P, Wagman RB (2006) Rationale, objectives and design of the Direct Analysis of Nonvertebral Fracture in the Community Experience (DANCE) study. Osteoporos Int 17:85–90CrossRefPubMed

64.

Sebba A, Sierra-Zorita R, Miller P, Chen P, Taylor K, Wong M, et al (2007) The Direct Assessment of Non-vertebral Fracture in the Community Experience (DANCE) study: baseline demographics and reasons for initiating teriparatide therapy. Presented at: Annual Meeting of the American Society for Bone and Mineral Research, September 16–19, Honolulu, HI, abstract W303

65.

Taylor K, Gold D, Silverman S, Chen P, Wong M, Krohn K (2007) Persistence with teriparatide therapy among participants in the DANCE trial. Presented at: Annual Meeting of the American Society for Bone and Mineral Research, September 16–19, Honolulu, HI, abstract W384

Title: Osteoporosis Therapies: Evidence from Health-Care Databases and Observational Population Studies
Author: Stuart L. Silverman
Publication date: 01-11-2010
Publisher: Springer-Verlag
Published in: Calcified Tissue International / Issue 5/2010
Print ISSN: 0171-967X
Electronic ISSN: 1432-0827
DOI: https://doi.org/10.1007/s00223-010-9400-1

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Osteoporosis Therapies: Evidence from Health-Care Databases and Observational Population Studies

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2010

Contribution of Mineral to Bone Structural Behavior and Tissue Mechanical Properties

Effects of Smoking on Severity of Disease in Primary Hyperparathyroidism

Circulating Fibroblast Growth Factor-23 Increases Following Intermittent Parathyroid Hormone (1–34) in Postmenopausal Osteoporosis: Association with Biomarker of Bone Formation

Effect of Risedronate on Osteocyte Viability and Bone Turnover in Paired Iliac Bone Biopsies from Early Postmenopausal Women

Intermittent PTH1–34 Causes DNA and Chromosome Breaks in Osteoblastic and Nonosteoblastic Cells

Potential of Resveratrol Analogues as Antagonists of Osteoclasts and Promoters of Osteoblasts

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page